CRVS Corvus Pharmaceuticals Inc.

6.03
+0.42  (+7%)
Previous Close 5.61
Open 5.61
Price To Book 1.76
Market Cap 176,841,207
Shares 29,326,900
Volume 237,766
Short Ratio
Av. Daily Volume 175,652

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b data at SITC November 2018 noted 1/33 PRs on monotherapy and 1/35 on combo.
CPI-444
Solid tumors - cancer
Phase 1/1b presentation at ASCO June 2019 - 4/12 patients noted stable disease.
CPI-006
Solid tumors
Phase 1/1b data due late 2019.
CPI-818
Peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL)

Latest News

  1. Need To Know: Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Insiders Have Been Buying Shares
  2. Corvus Pharmaceuticals Presents Initial CPI-006 Phase 1/1b Clinical Data at 2019 ASCO Annual Meeting
  3. Corvus Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference
  4. Edited Transcript of CRVS earnings conference call or presentation 9-May-19 8:30pm GMT
  5. Corvus Pharmaceuticals to Present Initial Clinical Data from CPI-006 Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
  6. Corvus: 1Q Earnings Snapshot
  7. Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2019 Financial Results
  8. Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2019 Financial Results on May 9, 2019
  9. Introducing Corvus Pharmaceuticals (NASDAQ:CRVS), The Stock That Slid 65% In The Last Three Years
  10. Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
  11. Corvus Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference
  12. Corvus Presents Updated Biomarker and Clinical Results from Lead Pipeline Programs CPI-444 and CPI-006 at Immuno-Oncology 360° Conference
  13. Corvus Pharmaceuticals to Present Updated Biomarker and Clinical Data on Lead Development Programs CPI-444 and CPI-006 at Immuno-Oncology 360° Conference
  14. Corvus Pharmaceuticals Announces Appointment of New Member of Board of Directors and Hiring of Chief Medical Officer
  15. Have Insiders Been Buying Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Shares This Year?
  16. Corvus Announces Presentation of Preclinical Data on CPI-818, a First-in-class Covalent Inhibitor of ITK Targeting T-Cell Lymphomas
  17. Corvus Announces Enrollment in Second Arm of Phase 1/1b Dose-Escalation Trial of Anti-CD73 Antibody, CPI-006, Focused on Combination with CPI-444 Adenosine Antagonist
  18. Ziopharm Oncology (ZIOP) in Focus: Stock Moves 6.2% Higher
  19. Sarepta Stock More Than Doubles This Year So Far: Here's Why
  20. Report: Exploring Fundamental Drivers Behind Berry Petroleum, Quotient, Virco Manufacturing, Corvus Pharmaceuticals, Marine Products, and Hamilton Beach Brands Holding — New Horizons, Emerging Trends, and Upcoming Developments